The FDA's stance on generics - at least on versions of the blood thinner Lovenox, such as Momenta Pharmaceuticals Inc.'s M-Enoxaparin (and probably similar compounds from Teva Pharmaceuticals Industries Ltd. and Amphastar Pharmaceuticals Inc. - became somewhat clearer last week, sadly and surprisingly for hanging-on Momenta investors who watched the stock's value tumble 58 percent, closing at $5.67. (BioWorld Financial Watch)